Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome

A retrospective study presented at the ACAAI 2026 meeting indicates that omalizumab treatment may eliminate the need for epinephrine in patients with alpha-gal syndrome. The findings suggest the drug provides a protective layer against severe allergic reactions to mammalian products.
Why it matters
This research offers a potential breakthrough in managing a complex and dangerous food allergy, improving quality of life for affected patients.
Among 64 patients with alpha-gal syndrome (AGS) treated with omalizumab (Xolair), none required epinephrine for a food-triggered reaction during therapy, according to a retrospective cohort analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona.¹
Despite strict avoidance of mammalian-derived foods and products, patients with AGS remain vulnerable to accidental exposures and recurrent anaphylaxis requiring epinephrine.¹ Real-world evidence on how omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, affects severe allergic outcomes in this population has been limited.¹
“These findings suggest that omalizumab may offer an additional layer of protection for patients living with alpha-gal syndrome,” said Collette Tilly, MD, lead author of the study and allergy & immunology fellow-in-training at the University of North Carolina at Chapel Hill, in a statement.
Omalizumab Efficacy in Alpha-Gal Syndrome: Epinephrine Use and Anaphylaxis Burden
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in